Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Granulocyte colony-stimulating factor (G-CSF) should be temporarily withheld in patients experiencing unresolved cytokine release syndrome. G-CSF administration can independently trigger low-grade fevers and acute inflammatory symptoms, obscuring whether the patient's presentation is an escalating immune toxicity, infection, or standard drug side effect.

Related Insights

The full FDA approval of the T-cell engager tarlatumab introduces significant logistical hurdles. Due to the high risk of Cytokine Release Syndrome (CRS), which occurred in over 50% of patients, the label requires 22-hour on-site monitoring after the first two doses. This presents practical challenges for outpatient infusion centers and requires new patient support infrastructure.

Prophylactically administering tocilizumab before bispecific antibody treatment can slash the incidence of cytokine release syndrome (CRS) from ~75% down to 20%. This simple intervention, analogous to using G-CSF for neutropenia, mitigates side effects and makes outpatient administration a much safer and more feasible option for patients.

A critical logistical challenge for administering Tarlatumab is ensuring patients with fever (a potential sign of CRS) are not left waiting in a standard emergency room. An effective strategy involves creating a dedicated protocol so these patients are seen immediately by staff familiar with the drug's toxicities, preventing dangerous delays.

The standard of care for CRS has evolved. Instead of waiting for CRS to escalate, institutions now immediately administer dexamethasone and tocilizumab at the first sign of a fever (grade 1), finding it doesn't harm CAR T-cell expansion and improves safety.

To manage the high risk of neutropenia with sacituzumab govitecan, prophylactic growth factor (G-CSF) use is becoming standard clinical practice. This is particularly true after the Day 8 administration. For some populations, like Asian patients, it is considered mandatory from the start, sometimes with a dose reduction.

Prophylactic G-CSF is used with sacituzumab govitecan not only to prevent febrile neutropenia but for practical reasons. It helps ensure patients' blood counts recover for their Day 8 dose, preventing treatment delays and simplifying scheduling for busy infusion centers.

When educating staff and patients about immunotherapies, it is helpful to distinguish between the desired effect (cytokine release killing cancer cells) and the dangerous toxicity (CRS). This reframing clarifies that CRS is an over-expression of the drug's intended mechanism, not a separate, unrelated side effect.

Abruptly stopping JAK inhibitors can trigger a potentially fatal SIRS-like syndrome from a cytokine storm. Clinicians must taper the dose. If an abrupt stop is necessary (e.g., for a procedure), bridging the patient with prednisone is a critical and effective strategy to prevent this severe withdrawal reaction.

While Cytokine Release Syndrome (CRS) and neurotoxicity (ICANS) are dramatic acute side effects, they are rarely fatal. The leading cause of non-relapse mortality for patients receiving CAR T-cells or bispecifics is infection resulting from prolonged cytopenias. This underscores the need for vigilant monitoring and prophylaxis.

Clinicians often conflate bispecific cytokine release syndrome with CAR-T CRS, creating undue reluctance in community settings. Bispecific grade 1 CRS typically presents with mild fevers (around 101°F) that rarely escalate into high-grade fevers (103°F–104°F) seen in CAR-T. In most cases, bispecific grade 1 CRS is safely controlled in the outpatient setting with acetaminophen, ibuprofen, or a single dose of oral dexamethasone.